News
Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...
Hims & Hers has delivered strong results and partnerships, but recent Cigna/Novo Nordisk news increases competitive risk and ...
Hims & Hers Health continues to fire on all cylinders as a business. Click here to read why HIMS stock is a Buy.
Investors are buying Hims & Hers Health ( HIMS 10.09%) stock hand over fist after the mail-order drugs company reported an earnings miss but a sales beat last night. But they're selling off shares of ...
With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.
1d
Investor's Business Daily on MSNNovo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli LillyNovo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.
Just 14 stocks with market caps above $1 billion have doubled so far this year. They probably aren't the winners you would ...
In an effort to promote the use of genuine products, Novo Nordisk is offering a one-time first-month offer for Wegovy at $199 ...
Hims & Hers Health (NYSE:HIMS) recently saw a significant stock price increase, jumping 140% over the past month. This rise ...
Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing ...
Medical pioneers Hims & Hers Health HIMS and Novo Nordisk NVO are making headlines this week after announcing a partnership to expand obesity care in the telehealth space. The long-term ...
We came across a bullish thesis on The Cigna Group (CI) on Antonio Linares’ Substack. In this article, we will summarize the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results